Spectral AI Shifts Toward Commercial Medical Technology

The company began manufacturing its first 30 DeepView AI systems and applied for Medicare add-on reimbursement tied to the device.

Updated on Nov. 21, 2026 in Healthcare

Spectral AI Shifts Toward Commercial Medical Technology

Spectral AI reported progress in moving from a research organization into a commercial medical technology enterprise during its third-quarter 2026 earnings call on November 10, 2026. The company began manufacturing its first 30 DeepView AI systems for BARDA-supported deployments at U.S. burn centers.

Why it matters

The company is moving away from government-funded research toward recurring software and service revenue, a shift it expects to build long-term margins. Its NTAP application to the Centers for Medicare and Medicaid Services, if approved, would give hospitals additional Medicare reimbursement for patients treated with the system.

Spectral AI began manufacturing 30 DeepView units and proposed a $2,750-per-patient Medicare add-on for hospitals, with commercial agreements running a minimum of three years. The source does not state whether CMS will approve the reimbursement request or how quickly commercial sales will reach the company's 2026 target.

The players

Spectral AI

Spectral AI is a medical technology company developing AI-based diagnostic tools for wound and burn assessment, and it is publicly traded.

Centers for Medicare and Medicaid Services

The Centers for Medicare and Medicaid Services is the federal agency that administers Medicare and reviews add-on payment applications such as NTAP requests.

The details

Spectral AI's commercial agreements pair device purchases or leases with recurring software and service revenue, and the company has targeted commercial sales for 2026. Management expects that as the installed base grows, commercial work will deliver higher margins than development work, with routine burn care as the main expansion target beyond mass-casualty preparedness.

Timeline

  1. Early in Q3 2026: Spectral AI submitted its NTAP application to the Centers for Medicare and Medicaid Services.

  2. Q3 2026: The company began manufacturing its first 30 DeepView AI systems.

  3. November 10, 2026: Spectral AI held its third-quarter 2026 earnings call.

  4. 2026: Commercial sales of DeepView are targeted to begin.

Healthcare Landscape

Spectral AI's NTAP application places it within the Medicare New Technology Add-on Payment program, which helps hospitals absorb the higher cost of newly approved technologies during their early adoption period. The company's move toward recurring software revenue reflects a broader push by medical device makers to secure reimbursement pathways that support commercial scale.

If CMS approves the NTAP application, hospitals using DeepView would receive an additional $2,750 per patient in Medicare reimbursement, which could affect whether burn centers adopt the system. The source does not indicate whether patients would see changes in their treatment or out-of-pocket costs.

The takeaway

Medical device companies increasingly depend on reimbursement approval as much as clinical results, so the outcome of the NTAP request will shape whether DeepView becomes a routine hospital expense. Watch for CMS's decision to see whether the commercial shift Spectral AI describes can be sustained.

Further reading

For more on the sector, see Healthcare coverage across the United States.

Source note: This article includes information reported by The Motley Fool.